These findings have become indicative not only for diagnosis, so much that the presence of the JAK2 V617F mutation has been introduced as a major criterion in the diagnosis of PV since 2008, but also for treatment, most recently culminating in the approval of JAK inhibitors as an alternative for patients who are resistant or intolerant to HU [1]. Here, JAK2 is linked to acquired polycythemia vera.